This year, the Food and Drug Administration will consider several applications for vaccines and a monoclonal antibody to prevent respiratory syncytial virus, or RSV, illness. We’ll go through some common questions about RSV and the potential vaccines for older adults in this story.
Moderna’s CEO said in January that the company’s total production in 2019 was “100,000 dose,” referring to all its vaccines and therapeutics. Online posts distorted the remarks to falsely claim Moderna made COVID-19 vaccines “before the pandemic started.” Moderna’s first batch of COVID-19 vaccines wasn’t ready until February 2020.
Government health agencies disclosed a potential safety concern for strokes in those 65 and older with one of the COVID-19 vaccines, but the agencies haven’t found any causal relationship and the concern was flagged by just one of several monitoring systems. Anti-vaccine campaigners, however, have wrongly claimed the agencies have found a link between the boosters and strokes.
The Centers for Disease Control and Prevention hosted an online seminar about the treatment of blood clots, which is expected to grow as the U.S. population ages and the obesity rate increases. But some vaccine opponents misrepresented the webinar to falsely suggest that the projected rise in blood clots is related to the COVID-19 vaccines.
Denmark announced a plan for its fall COVID-19 vaccination drive, saying it will offer omicron-specific booster shots to high-risk individuals, including everyone 50 and over. But U.S.-based misinformation peddlers misleadingly suggest that means the shots are unsafe for those under 50. The Danish Health Authority said that is a misinterpretation.
A post published in English and Spanish repeats the debunked idea that the current monkeypox outbreak might have resulted from a virus that was created in a lab. The post also baselessly alleges that the World Health Organization’s decision to declare the outbreak a public health emergency was due to financial incentives.